312 related articles for article (PubMed ID: 23509325)
1. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
[TBL] [Abstract][Full Text] [Related]
2. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
3. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
4. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
Kamashev D; Vitoux D; De Thé H
J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
[TBL] [Abstract][Full Text] [Related]
5. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
6. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J
PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106
[TBL] [Abstract][Full Text] [Related]
7. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
8. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
9. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
10. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
11. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
12. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
13. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
14. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
15. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Dos Santos GA; Kats L; Pandolfi PP
J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243
[TBL] [Abstract][Full Text] [Related]
16. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
17. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
Shao W; Benedetti L; Lamph WW; Nervi C; Miller WH
Blood; 1997 Jun; 89(12):4282-9. PubMed ID: 9192750
[TBL] [Abstract][Full Text] [Related]
18. How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
Korsos V; Miller WH
J Mol Endocrinol; 2022 Nov; 69(4):T69-T83. PubMed ID: 36112505
[TBL] [Abstract][Full Text] [Related]
19. Modified array-based comparative genomic hybridization detects cryptic and variant PML-RARA rearrangements in acute promyelocytic leukemia lacking classic translocations.
Gruver AM; Rogers HJ; Cook JR; Ballif BC; Schultz RA; Batanian JR; Fesler MJ; Tubbs RR
Diagn Mol Pathol; 2013 Mar; 22(1):10-21. PubMed ID: 23370423
[TBL] [Abstract][Full Text] [Related]
20. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
